2017 US Medicinal Products
Financial Strength Rankings using Artificial Intelligence
Top rated | 11 of 44 |
Best rating | 168 % |
Worst rating | -2,028 % |
New companies | |
Negative Economic Capital Ratio | 15 of 44 |
Financial Strength Rankings using Artificial Intelligence
Top rated | 11 of 44 |
Best rating | 168 % |
Worst rating | -2,028 % |
New companies | |
Negative Economic Capital Ratio | 15 of 44 |
Revenues | 24.9 B |
Assets | 34.1 B |
Expenses | 24.5 B |
Stockholders Equity | 12.0 B |
Unprofitable Companies | 26 of 44 |
On February 14th, 2024, something momentous happened. Nvidia, the chip and graphics card [...]
Source: https://openai.com/dall-e-3/ The results for RealRate’s 2023 ranking for U.S. Pharma are [...]
Source: https://openai.com/dall-e-3/ The results for RealRate’s 2023 ranking for U.S. Savings are [...]
Source: https://openai.com/dall-e-3/ The results for RealRate’s 2023 ranking for U.S. Chemicals are [...]
Source: https://openai.com/dall-e-3/ The machines have emerged and the results for RealRate’s 2023 [...]
Source: https://openai.com/dall-e-2/ The results for RealRate’s 2023 ranking for U.S. Medicinal Products [...]
Source: https://openai.com/dall-e-2/ The results for RealRate’s 2023 ranking for U.S. Non-Life Insurance [...]
Source: https://openai.com/dall-e-2/ The results for RealRate’s 2023 ranking for U.S. Spacs are [...]
This year's rating information is fee-based. Please request rates at
james.woods@realrate.ai